[ad_1]
When Patrick Duffy began its work at the Walter Reed Army Institute of Research in 1991, scientists had already for several years tested the first vaccine that would protect against malaria. Thirty years later, the World Health Organization said finally encouraged The results of this study include the intervention of malaria in children under 5 years of age in Africa. The RTS, S vaccine, also called Mosquirix, is the first vaccine against the virus.
Duffy, now director of the Laboratory of Malaria Immunology and Vaccinology at the National Institute of Allergy and Infectious Diseases, is pleased with its potential to reduce the number of diseases that kill more than 400,000 people each year. But he is well aware that the vaccine is not a universal solution. “This prevents medical malaria in children,” he says. But it does not stop the spread of the virus from mosquitoes to humans, and it does not protect anyone at risk. “What about pregnant women? What about removal? ”He asks. “I feel like that’s why things can change.”
Scientists at the GlaxoSmithKline (GSK) first-generation RTS, S in the 1980s, are targeting children under the age of 5, who count 65% die from malaria. Humans are immune to the virus in old age, so adults are less likely to become ill as children if they are infected. The vaccine is supposed to speed up the process, providing immunity to children until their immune system is strong.
But it took a long time to test the vaccine. GSK has partnered with organizations including Walter Reed, Bill and Melinda Gates Foundation, and hospitals in seven African countries to conduct clinical trials. The European Medicines Agency says the vaccine is safe and effective after a Phase III and GSK test from 2009 to 2011. 50% effective in preventing hypertension. But WHO staff have yet to confirm its effectiveness, as the vaccine requires four doses, given as a shot, after 18 months. So GSK launched another pilot program in 2019, testing the drug in Ghana, Kenya, and Malawi.
Although medical offices in each country should approve the vaccine, WHO’s recommendations are highly recommended. But expanding production to create millions of nations, developing medical systems to distribute them, and obtaining financial support from non-profits from other countries takes time. “There is still a lot of work to be done before vaccines become more widely available,” says Ashley Birkett, director of vaccine vacaria at PATH, a nonprofit that helped develop the vaccine.
Malaria is a virus that causes a person to change and live with people for thousands of years. Unlike respiratory viruses such as the flu that spreads through the air, malaria is spread by mosquitoes. They pick up the virus in the blood of infected people, then bite others in the area, and transmit the virus to them. Although the SARS-CoV-2 virus contains about 10 genes that register 29 proteins, Plasmodium falciparum, one of the five germ-causing germs, has a larger genome that supplies more than 5,000 proteins.
The virus also has many different functions in life. When infected mosquitoes bite, tiny sporozoites enter the bloodstream and travel to the liver, where they begin to multiply. They leave the liver and enter the heart, lungs, and bloodstream, where they transmit red blood cells and develop symptoms such as colds, nausea, and chills. In severe cases, malaria can cause brain damage, fainting, shortness of breath, and paralysis.
[ad_2]
Source link
